Cathepsin C activates serine proteases expressed in hematopoietic cells by cleaving an N-terminal dipeptide from the proenzyme upon granule packaging. The lymphocytes of cathepsin C–null mice are therefore proposed to totally lack granzyme B activity and perforin-dependent cytotoxicity. Surprisingly, we show, using live cell microscopy and other methodologies, that cells targeted by allogenic CD8+ cytotoxic T lymphocyte (CTL) raised in cathepsin C–null mice die through perforin-dependent apoptosis indistinguishable from that induced by wild-type CTL. The cathepsin C–null CTL expressed reduced but still appreciable granzyme B activity, but minimal granzyme A activity. Also, in contrast to mice with inactivation of both their granzyme A/B genes, cathepsin C deficiency did not confer susceptibility to ectromelia virus infection in vivo. Overall, our results indicate that although cathepsin C clearly generates the majority of granzyme B activity, some is still generated in its absence, pointing to alternative mechanisms for granzyme B processing and activation. Cathepsin C deficiency also results in considerably milder immune deficiency than perforin or granzyme A/B deficiency.
Skip Nav Destination
Article navigation
12 February 2007
Article|
February 05 2007
Residual active granzyme B in cathepsin C–null lymphocytes is sufficient for perforin-dependent target cell apoptosis
Vivien R. Sutton,
Vivien R. Sutton
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Nigel J. Waterhouse,
Nigel J. Waterhouse
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Kylie A. Browne,
Kylie A. Browne
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Karin Sedelies,
Karin Sedelies
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Annette Ciccone,
Annette Ciccone
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Desiree Anthony,
Desiree Anthony
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Aulikki Koskinen,
Aulikki Koskinen
2Viral Immunology, Division of Immunology and Genetics, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia
Search for other works by this author on:
Arno Mullbacher,
Arno Mullbacher
2Viral Immunology, Division of Immunology and Genetics, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia
Search for other works by this author on:
Joseph A. Trapani
Joseph A. Trapani
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Search for other works by this author on:
Vivien R. Sutton
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Nigel J. Waterhouse
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Kylie A. Browne
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Karin Sedelies
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Annette Ciccone
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Desiree Anthony
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Aulikki Koskinen
2Viral Immunology, Division of Immunology and Genetics, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia
Arno Mullbacher
2Viral Immunology, Division of Immunology and Genetics, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia
Joseph A. Trapani
1Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
Correspondence to Joseph A. Trapani: [email protected]
Abbreviations used in this paper: AV, annexin V; BLT, Na-CBZ-L-lysine thiobenzyl ester; Cat, cathepsin; CTL, cytotoxic T lymphocyte; ECTV, ectromelia virus; NE, neutrophil elastase; NK, natural killer; PI, propidium iodide; PLS, Papillon-Lefevre syndrome.
Received:
September 13 2006
Accepted:
January 06 2007
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2007
J Cell Biol (2007) 176 (4): 425–433.
Article history
Received:
September 13 2006
Accepted:
January 06 2007
Citation
Vivien R. Sutton, Nigel J. Waterhouse, Kylie A. Browne, Karin Sedelies, Annette Ciccone, Desiree Anthony, Aulikki Koskinen, Arno Mullbacher, Joseph A. Trapani; Residual active granzyme B in cathepsin C–null lymphocytes is sufficient for perforin-dependent target cell apoptosis . J Cell Biol 12 February 2007; 176 (4): 425–433. doi: https://doi.org/10.1083/jcb.200609077
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement